AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma

RegulatoryapprovedTepkinlyPositive

AI Analysis

Summary

AbbVie and Genmab received EU regulatory approval for a label expansion of Tepkinly in follicular lymphoma, expanding the drug's approved indications in Europe.

Outcome Details

EU label expansion granted for Tepkinly in follicular lymphoma

Importance:7/10

Sentiment:

0.80

regulatory approvallabel expansionEU approvaloncologyfollicular lymphoma

Related Companies

$ABBV $GMAB

Read the original article

Published by Seeking Alpha Healthcare on July 7, 2026 4:38 PM

Read Original